Floatz logo

Entrectinib

Primary Brain Tumors

Hoffmann-La RocheSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Primary Brain Tumors cohort.

Asset / SponsorPhaseRating
4-demethyl-4-cholestryloxycarbonylpenclomedine
DEKK-TEC, Inc.
Phase 2B
Rvp-001
Reveal Pharmaceuticals Inc.
Phase 2B
5-ala
Constantinos Hadjipanayis
Phase 2CCC
Capecitabine
Northwell Health
Phase 1/2CCC
(+)-VINCRISTINE
H. Lee Moffitt Cancer Center and Research Institute
Phase 1CC

View all 28 →

Same molecule, other indications

Entrectinib is also rated in:

hematopoietic and lymphoid system neoplasmDormant
BB
Indicative ·
64 / 100
View asset →
Anatomic Stage IV Breast Cancer AJCC v8Dormant
B
Indicative ·
62 / 100
View asset →
sarcomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →